|
|
|
| Untersuchte Arbeit: Seite: 13, Zeilen: 1-11 |
Quelle: Milhavet et al 2003 Seite(n): 643, Zeilen: 643:li.Sp. 21ff |
|---|---|
| 1.2.2.1 Cancer
There are two general abnormalities in cancer cells that exhibit a dysregulation of the cell cycle resulting in uncontrolled growth and are resistant to death as a result of abnormalities in one or more proteins that mediate apoptosis (Nam and Parang, 2003). The goals for RNAi approaches for cancer therapy are therefore to silence the expression of a cell cycle gene and/or an anti-apoptotic gene in the cancer cells thereby stopping tumor growth and killing the cancer cells. To selectively eliminate cancer cells without damaging normal cells, the RNAi needs to be targeted to a gene specifically involved in the growth or survival of the cancer cell, or the siRNAs would be selectively delivered into the cancer cells. Nam NH, Parang K. Current targets for anticancer drug discovery. Curr Drug Targets. 2003 Feb;4(2):159-179. |
A. Cancer
There are two general abnormalities in cancer cells — they exhibit dysregulation of the cell cycle resulting in uncontrolled growth and they are resistant to death as a result of abnormalities in one or more proteins that mediate apoptosis (Nam and Parang, 2003). The goals for RNAi approaches for cancer therapy are therefore to knock out the expression of a cell cycle gene and/or an anti-apoptotic gene in the cancer cells thereby stopping tumor growth and killing the cancer cells. To selectively eliminate cancer cells without damaging normal cells, the RNAi would be targeted to a gene specifically involved in the growth or survival of the cancer cell, or the siRNAs would be selectively delivered into the cancer cells. Nam NH and Parang K (2003) Current targets for anticancer drug discovery. Curr Drug Targets 4:159–179. |
Ohne Hinweis auf eine Übernahme. |
|